drugset
drugset / Trial / NCT04971135

First-in-human Study of SAN711 in Healthy Participants

NCT04971135 ↗

Phase 1 Unknown 80 enrolled Saniona Medpace, Inc. · collab
RandomizedParallel-groupQuadruple-blindOther

Summary

Phase 1, first-in-human, double-blind, randomized, placebo-controlled, parallel group, single ascending dose (SAD) and multiple ascending dose (MAD) study

Timeline

Start
2021-06-30
Primary completion
2022-06
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SAN711 Unknown — —

Indications

No indication recorded.